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Abstract: Solid organ transplantation has emerged as the “gold standard” therapy for end-stage organ failure as it im-
proves both quality of life and survival. Despite the progress in short-term graft survival, that is closely associated with 
the impressive reduction of acute rejections within the first year, long-term graft and patient survival remain almost un-
changed and unsatisfactory. Incomplete control of chronic allograft injury but particularly the adverse effects of 
long-term immunosuppression, such as graft toxicity, diabetes, cardiovascular events, infections, and tumours continue 
to challenge the long-term success. In general, immunosuppression is applied as one-size-fits-all strategy. This can re-
sult in over- and under-immunosuppression of patients with low and high allo-responsiveness, respectively. Trial- and 
-error strategies to minimize or even completely wean of immunosuppression have a high failure rate. Consequently, 
there is an unmet medical need to develop biomarkers allowing objective risk stratification of transplant patients. To 
achieve this goal, we engaged in an academic-industrial partnership. The central focus of the European-wide BIO-DrIM 
consortium (BIOmarker-Driven IMmmunosuppression) is the implementation of biomarker-guided strategies for per-
sonalizing immunosuppress- ion to improve the long-term outcome and to decrease the adverse effects and costs of 
chronic immunosuppression in solid organ transplant patients. The concept includes four innovative investigator-driven 
clinical trials designed by the consortium. 
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Introduction 
olid organ transplantation (SOT) is well estab-
lished to date but despite the progress in short- 
term allograft survival, that is closely associated 
with the impressive reduction of acute rejections 
within the first year, long-term graft and patient sur-
vival remain almost unchanged and unsatisfactory. 
Chronic rejection is not well controlled yet. In partic-
ular, however, the adverse effects of long-term immu-
nosuppression, such as graft toxicity, diabetes, cardi-
ovascular events, infections, and tumours endure to 
challenge the long-term success of transplantation. 
Moreover, multidrug treatment and side effects de-
crease the patients’ adherence to the therapy.  
Therefore, the paradigm of immunosuppression in 
transplant patients is presently shifting from the recent 
focus on searching for novel drugs to further increase 
“net”-immunosuppression, to the concept of minimiz-
ing long-term immunosuppression “as much as feasi-
ble” and “as early as possible”. Intensive research is 
currently on-going to improve the treatment complex-
ity and thus improve the adherence of patients, reduce 
the burden of side effects and decrease the cost of 
therapy.  
Very few patients (liver > kidney transplantation) 
can be completely weaned-off immunosuppression; 
when achieved, this clinical outcome suggests patients 
are operationally tolerant. At least for liver recipients, 
there are data to suggest that the longer the period 
post-transplant, the higher the chance to become im-
munosuppressive drug-free. A significant proportion 
of patients (low-responders) can be maintained on 
immunosuppressive monotherapy (liver > kidney, the 
longer post-transplantation the more frequent), but 
others (high-responders) develop accelerated chronic 
rejection despite maintaining combined standard im-
munosuppression. These observations were almost 
completely generated by “trial and error” observation-
al studies and warrant an unmet need to stratify trans-
planted patients regarding their immunological res-
ponsiveness to the allograft and define their individual 
need of immunosuppression. 
As suggested, in order to decrease the adverse ef-
fects and costs of long-term combinatory high-dose 
immunosuppression in allograft recipients, many clin-
ical trials have been conducted in which completely 
different immunosuppression minimization strategies 
have been used (mostly steroid withdrawal, conver-
sion from calcineurin inhibitors [CNI] to mTOR inhi-
bitors, CNI avoidance, or early monotherapy by use of 
new biologicals). In kidney transplant patients, com-
plete weaning was mostly either the result of the phy-
sician´s reaction to severe complications (e.g. 
Post-Transplant Lymphoproliferative Disease, BKV- 
nephropathy) or compliance issues by the patient. By 
contrast, the higher incidence of spontaneous opera-
tional tolerance and the high regenerative capacity of 
liver following reversal of on-going rejection allowed 
targeted drug weaning studies in long-term liver allo-
graft recipients. Despite some very promising results, 
the outcome is not satisfactory[1,2]. Minimization, even 
a moderate one, is failing in many patients and com-
plete weaning is only rarely successful (liver > kid-
ney). A disadvantage and major limitation of almost 
all studies so far has been the absence of patient strati-
fication and follow-up monitoring using biomarkers in 
order to identify the right patient, time point, and mi-
nimization protocol as well as to detect the success or 
even more the failure, before clinical signs of rejection 
occur — in other words, clear evidence of persona-
lized immunosuppression is missing.  
From all emerging biomarkers, whose implementa-
tion might be of benefit for transplant medicine, only 
a few candidates have reached the methodical and 
diagnostic level that is suitable for clinical deci-
sion-making. With the exception of the detection of 
humoral sensitization by screening for panel-reactive 
and donor-specific anti-HLA and non-HLA alloanti-
bodies that indicates a high-risk for SOT recipients, no 
S 
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any other marker reached the level of a stratification 
marker that is applied in daily routine. In other words, 
we are far away from personalized immunosuppres-
sion but apply immunosuppression according to 
one-size-fits-all in two categories only (risk group 
according to humoral sensitization or medical history 
of recent graft loss by immunological reasons). How-
ever, we know about the presence of distinct individu-
al immune responsiveness and related risk of rejection 
(Figure 1). There are multiple reasons favouring this 
situation: 
(i) The development, validation, and implementa-
tion of a biomarker, in particularly if used for deci-
sion-making (companion diagnostics), is a long-last-
ing and costly procedure. Almost all academic studies 
performed so far do not jump about the road blocks on 
the way from marker discovery to an approved test 
(Figure 2).  
(ii) For decades biomarker discovery was mostly 
focused on the non-invasive detection/prediction of 
rejection. However with the appearance of the more 
recent immunosuppressive protocols, rejection is a 
much lesser clinical problem than before. Search for 
markers allowing the stratification of patients into 
high- and low-responders or even operationally tole-
rant patients only became more popular during the last 
few years after realizing that many patients are over- 
immunosuppressed, and on contrary, some develop 
spontaneous operational tolerance without need for 
any immunosuppression. 
(iii) The pharmaceutical industry did have limited 
interest (and experienced limited pressure by the 
health systems) to invest into costly companion diag-
nostics that may result in splitting of the market for a 
particular drug. 
Methodical and clinical biomarker validations re-
quire interdisciplinary multicenter efforts, including 
academic/industry partnerships. Based on the biomar-
ker discovery and exploratory clinical results of the rec-
ent European networks sponsored within the 6th  
 
 
 
Figure 1. From “one-size-fits-all” to a biomarker-driven strategy after solid organ transplantation. 
Presently, patients at enhanced risk for rejection post SOT are stratified by pre-transplant alloantibody screening and medical history only. Generally, 
patients are treated according to the more or less “one-size-fits all” strategy in those groups (adaption only in case of adverse effects), although tri-
al-and-error minimization studies demonstrated heterogeneity in immune responsiveness among the graft recipients. Perioperative stratification by 
validated immunological biomarkers might allow safe early drug minimization. Moreover, detection of operationally tolerant patient among stable 
long-term allograft recipients might allow even safe complete weaning of immunosuppression in a subset of patients. 
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Figure 2. Long-way to biomarker-driven immunosuppression. 
Most biomarker studies exploring companion diagnostics for guiding immunosuppression after solid organ transplantation that are published so far, 
do not reach sufficient levels of methodical and clinical validation (road blocks are indicated as ). BIO-DrIM addresses several milestones on the 
way to personalized immunosuppression. 
 
 
framework, “Indices of Tolerance (IOT)” and “Repro-
gramming the Immune System for the Establishment 
of Tolerance (RISET)”[3–16], the concept of the “Bio-
marker-driven Immunosuppression (BIO-DrIM)” con-
sortium has been developed and is sponsored by the 7th 
framework of the European Commission (www.bio-
drim.eu). The academic partners of the consortium are 
well experienced in performing clinical trials in SOT 
patients as well as the development, validation, and 
performance of biomarkers. The early partnering of 
small and medium-sized enterprises (SME´s) and di-
agnostic industry with experiences in the development 
and commercialisation of in vitro diagnostics (IVD) 
helps to implement standardized test procedures and 
will allow a fast translation of the results into bio-
marker product development. The embedding of pro-
fessional health-economic studies into all the bio-
marker trials will deliver cost/benefit data that are 
useful for the discussions following with health in-
surances following marker approval regarding reim-
bursement options. Finally, the big pharma partner 
within the BIO- DrIM consortium supports the per-
formance of challenging clinical trials. The BIO- 
DrIM consortium has/had to face several challenges 
on the way to personalized immunosuppression that 
will be discussed in this paper.   
Material and Methods 
Structure and Specific Aims of the BIO-DrIM 
Consortium 
The BIO-DrIM (BIOmarker-Driven IMmunosppres-
sion) consortium has been founded at 2013 with the 
support of the 7th framework program of the European 
Commission. The full title of the project reads: “Per-
sonalized minimization of immunosuppression after 
solid organ transplantation by biomarker-driven strati-
fication of patients to improve long-term outcome and 
health-economic data of transplantation”. BIO-DrIM 
consists of nine academic partners (Amsterdam, Bar-
celona, Berlin, Hamburg, London, Nantes, Oxford, 
Prague, and Regensburg) and six industry partners 
covering well recognized experiences in clinical 
management of SOT patients (academic partners), 
development, validation, and implementation of bio-
markers (academic partners), diagnostic test develop-
ment and marketing (Beckman-Coulter Immunotech, 
Genome Identification Diagnostics (GenID)/Autoimmune 
Diagnostics (AID), Milenia Biotec), health eco-
nomic analyses (Cellogic), drug development and 
marketing (Teva), and management of consortia (Alta) 
(Figure 3). 
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Figure 3. The BIO-DrIM consortium. 
The European consortium for “Biomarker-driven Immunosuppression (BIO-DrIM)” (funded by 7th EU-framework) consists of nine academic partners 
(Amsterdam, Barcelona, Berlin, Hamburg, London, Nantes, Oxford, Prague, and Regensburg) and six industry partners covering well recognized 
experiences in clinical management of SOT patients (academic partners), development, validation, and implementation of biomarkers (academic 
partners), diagnostic test development and marketing (Beckman-Coulter Immunotech, Genome Identification Diagnostics (GenID) / Autoimmune 
Diagnostics (AID), Milenia Biotec), health economic analyses (Cellogic), drug development and marketing (Teva), and management of consortia 
(Alta). 
 
The program is structured into six work packages 
(WPs): 
WP1 Targeted complete and partial weaning of 
immunosuppression in long-term stable liv-
er and kidney transplant patients characte-
rized as low-responders and identified by 
the recently established tolerance signature 
biomarker tests 
WP2  Prevention of the high-dose standard im-
munosuppression in low-responder kidney 
transplant recipients identified by periopera-
tive patient stratification 
WP3 Increasing the population of kidney trans-
plant patients belonging to the low-respon-
der group by early targeting of recently ac-
tivated alloreactive effector/memory T cells 
WP4 Biomarker analyses, data management & 
biostatistics, health-economic analyses, and 
IVD test development 
WP5 Mechanisms behind successful minimizing 
immunosuppression explored in preclinical 
studies 
WP6 Dissemination, training and other activities 
BIO-DrIM aims to implement biomarker-guided 
strategies for personalizing immunosuppression in 
order to improve the long-term outcome and to de-
crease the adverse effects and costs of chronic immu-
nosuppression in SOT patients. The concept includes 
four innovative investigator-initiated clinical trials 
(IITs) designed by the consortium. The expected re-
sults of the BIO-DrIM project will be: 
(i) Targeted complete/partial weaning of standard 
immunosuppression in long-term stable liver and kid-
ney transplanted patients identified as "operationally 
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tolerant" by recently developed biomarker panels 
 Stratification into tolerant vs non-tolerant pa-
tients for safe weaning-off immunosuppression 
(ii) Prevention of high-dose standard immunosup-
pression in low-responder kidney transplant recipients 
by perioperative biomarker-driven stratification 
 Stratification into low- vs high-responder pa-
tients for guided immunosuppression 
(iii) Shifting high-responder into low-responder 
kidney transplant patients who might be suitable for 
early minimization by the recently explored selective 
targeting of alloreactive effector/memory T cells 
 Using tolerance/rejection biomarker monitoring 
as surrogate markers 
(iv) Implementing new biomarker candidates sup-
porting personalized immunosuppression within the 
clinical trials 
 Biomarker discovery and PoC analyses 
(v) Analysing the health-economic impact of bio-
marker-guided immunosuppression 
 The interesting exploitable potential 
(vi) Studying the mechanisms behind successful 
weaning (regulation/effector balance) 
 The mechanisms of success vs. failure of 
minimizing immunosuppression 
(vii) Disseminating the results and developing 
commercialization by partnering with SME/industry 
 Translation from clinical research to the broad 
implementation into clinical practice 
Biomarker Tests 
The biomarker platforms of BIO-DrIM consist of the 
following methods selected from previous work: 
(i) Elispot platform: Interferon-gamma (IFN-ga-
mma) Elispot-Assay for detecting donor-reactive 
memory/effector T cells[11,12,17] 
 Decision-making parameter (candidate for 
companion diagnostics) 
(ii) Real-time RT-PCR platform: Gene panel ex-
pression analysis to identify molecular tolerance (and 
rejection) signatures[4–10,18,19] 
 Decision-making parameter (candidate for com-
panion diagnostics) 
(iii) Multiparameter flowcytometry platform: Sev-
eral 10-color panels for the characterization of circu-
lating immune cell subsets[20–22] 
 Exploratory test to detect patients at risk (high- 
responder) and to monitor therapy response 
(iv) Ligand assay platform: Multiplex and Singlep-
lex Elisa-based tests for quantification of cytokines in 
blood and urine[23,24] 
 Exploratory test to detect graft injury and to 
monitor minimization strategies 
The tests are performed either in a core laboratory 
(gene expression, urinary cytokine levels) or in the on- 
site laboratories of different clinical centres under the 
guidance and control of a central core laboratory (all 
others). 
Additionally, new biomarker tests/test platforms 
(e.g. T-cell receptor DNA and whole genome RNA 
expression by Next-Generation Sequencing, new mul-
tiplex ligand assay platforms) are explored in accom-
panying analyses by the on-site laboratories at differ-
ent centres[25–31].  
Results 
Design of the Clinical Trials 
The BIO-DrIM consortium will perform several clini-
cal trials for the clinical validation of biomarkers 
within WPs 1–3. Two of them will use worldwide for 
the first time biomarkers as “decision makers” (com-
panion diagnostics) in randomized multicentre studies 
after SOT.   
LIFT — Molecular tolerance signature for guiding 
immunosuppression withdrawal in stable long-term 
liver transplant patients (biomarker-driven multicen-
tre intervention study) 
In contrast to other organs, following liver trans-
plantation significant number of patients can stop im-
munosuppression without undergoing rejection. This 
phenomenon is known as operational tolerance. Sev-
eral studies of medically-supervised immunosuppres-
sion withdrawal have been performed after liver 
transplantation. Until recently, however, it had been 
impossible to discriminate between recipients who 
could safely wean their drugs and those who could not. 
As a result, a large proportion of liver patients enr-
olled in immunosuppression withdrawal studies expe-
rienced rejection episodes. While the rejection epi-
sodes occurring within these closely monitored trials 
can be easily reversed in the large majority of cases, a 
small risk of irreversible graft damage remains. As a 
consequence, immunosuppression withdrawal remains 
an experimental procedure only performed in selected 
liver transplant units across the world. This includes 
efforts of the preliminary work of members of the 
BIO-DrIM consortium that formed the basis for this 
new trial described here. Thus, in the withdrawal trial 
recently completed by Sanchez-Fueyo et al., of 98 
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selected recipients undergoing weaning, 42% achieved 
successful immunosuppression withdrawal[18].  
The success rate was greatly influenced by how 
long after transplant was weaning attempted. For pa-
tients between 3 and 6 years post-transplant at the 
time of initiating weaning, only 12% achieved suc-
cessful drug withdrawal (and all of them were >50 
years of age). In contrast, patients 6–11 years post- 
transplant experienced a success rate of 38%, and in 
those >11 years post-transplant, the success rate was 
80%, regardless of recipient age[32]. In contrast, a re-
cent trial on early weaning during the 1st year failed 
completely despite using a “pro-tolerogenic” proto-
col[33]. To identify the state of operational tolerance 
and predict the development of rejection following 
withdrawal, Sanchez-Fueyo performed several gene 
expression studies for discovering and validating a 
biomarker signature[4]. Whole genome gene expres-
sion studies in peripheral blood comparing success-
fully vs unsuccessfully weaned liver transplant reci-
pients revealed a particular molecular tolerance sig-
nature[3]. However, this peripheral blood profile of 
successfully weaned patients could not be confirmed 
as predictive for successful withdrawal if analysed in 
patients before initiating weaning in a prospective trial. 
Obviously, the presence of immunosuppression in op-
erational tolerant patients before weaning has a sig-
nificant impact on the gene expression pattern in pe-
ripheral blood, overlapping with the tolerance signa-
ture. Remarkably, however, the analysis of gene ex-
pression in liver biopsies collected before initiating of 
weaning revealed a robust tolerance signature pre-
dicting successful withdrawal[34].  
A specific combination of gene expression markers 
in allograft biopsies was highly accurate in predicting 
drug withdrawal outcome. Interestingly, the signature 
was more associated with the iron metabolism as di-
rectly with immune markers[34]. Iron metabolism has, 
however, indirect impact on immune reactivity[35].  
This novel technology could constitute the basis of 
a diagnostic test for detecting tolerance capable of 
identifying operationally tolerant recipients before an 
attempt at immunosuppression withdrawal is made. 
Such a test would radically change the long-term 
management of liver transplant recipients and would 
have a great beneficial impact in the well-being and 
quality of life of liver. Before this novel strategy can 
be applied to routine clinical practice, however, it 
needs to be validated within a large clinical prospec-
tive multicentre study. This is addressed in the ongo-
ing “Prospective randomised biomarker-based trial to 
assess the risk-benefit ratio of a biomarker-guided 
immunosuppression withdrawal strategy in liver 
transplantation” (LIFT) supported by BIO-DrIM and 
MRC/NHS (PI: A. Sanchez-Fueyo, KCL).  
The hypothesis of the current study is that the use 
of an in vitro transcriptional test of operational toler-
ance to stratify liver transplant recipients undergoing 
immunosuppression withdrawal results in an accurate 
identification of tolerant recipients and reduces the 
rate of rejection. To demonstrate this hypothesis, bio-
marker-based stratification must be non-inferior with 
respect to the number of successfully weaned patients, 
and superior with respect to the proportion of rejection 
episodes. 
The main objective of the current study is to deter-
mine whether this novel molecular test of tolerance 
can be employed to optimise immunosuppression 
withdrawal protocol so that only operationally tolerant 
recipients are weaned-off drugs and the risk of rejec-
tion can be substantially reduced. In order to do so, 
liver transplant recipients who are 3 or more years 
post-transplant and who are eligible for drug with-
drawal will undergo a liver biopsy to rule out the 
presence of occult rejection and to conduct the mole-
cular test of tolerance. Patients will then be randomly 
allocated to two different strategies of gradual immu-
nosuppression withdrawal. In the first group of pa-
tients, immunosuppression withdrawal will be per-
formed in all recipients independent on the biomarker 
signature. In the second group, only those patients 
with a positive diagnostic test of tolerance will be 
weaned off immunosuppression, while patients with a 
negative tolerance signature will be kept on mainten-
ance immunosuppression. By comparing the outcome 
of the two strategies we will be able to evaluate the 
clinical utility of the diagnostic test. In patients with a 
negative diagnostic test and regulated on immunosup-
pressive medication the test will be repeated at the end 
of the study to assess their phenotype has changed 
over time. Additional experiments will be performed 
to gain a precise understanding on the mechanisms 
responsible for the development of transplantation 
tolerance.   
A total of 156 liver recipients will be enrolled in 
several European Liver Transplant Units. Patients will 
be enrolled over 18 months, and immunosuppressive 
drugs will be discontinued over 6–9 months. Patients 
will be followed-up for 3 additional years after com-
plete drug withdrawal and the total study duration will 
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be 70 months.    
Cellimin — a prospective donor-specific Cellular 
alloresponse assessment for immunosuppression mi-
nimization in de novo renal transplantation (biomark-
er-driven multicentre intervention study)  
The current immunosuppressive therapy mainly 
consists from the combination of three to four immu-
nosuppressant agents. Minimizing immunosuppres-
sion, e.g. monotherapy, as early as possible without 
losing control of acute/chronic rejections would be 
already of great benefit and could reduce adverse ef-
fects and costs. However, this is only possible in a 
minority of patients as yet. Therefore, a precise evalu-
ation of the anti-donor alloimmune responsiveness in 
order to identify patients likely to accept the graft with 
no or very low immunosuppression would be of great 
value. One of possible approaches is the tacrolimus 
(TAC) monotherapy avoiding corticosteroids and an-
ti-proliferative agents (mycophenolate mofetil — 
MMF), which may lead to substantial reduction of the 
immunosuppressive load and improve the cardiovas-
cular risk profile. Several studies on TAC monothera-
py were already published in the area of kidney trans-
plantation. Although most of them reported relatively 
positive results with monotherapy, biopsy-proven 
acute rejection (BPAR) rates were significantly higher 
as compared to standard of care immunosuppression, 
despite using relatively high TAC trough levels which 
also negatively impacted to the 6/12-month allograft 
function. Other attempts for TAC monotherapy have 
been done in non-randomized, single centre pilot stu-
dies, especially using T-cell depleting agents such as 
alemtuzumab with rather contradictory and inconclu-
sive results.  
The assessment of the immunologic risk is exclu-
sively based on the detection of preformed circulating 
alloantibodies, with the assumption that humoral allo-
sensitization also illustrates the allospecific T-cell ef-
fector/memory immune response. This is of great im-
portance, as it is well known that cellular memory 
may occur without humoral activation and that allo-
reactive cellular responses are key players in initiating 
and mediating allograft rejection[11]. In fact, with the 
current accurate screening of humoral sensitization, 
rates of antibody-mediated rejection (ABMR) have 
significantly been reduced but T-cell mediated acute 
and chronic rejection (TCMR) is still observed after 
renal transplantation, especially among patients not 
receiving standard CNI-based at least triple drug im-
munosuppression. A noteworthy point is that, in the 
last years, attempts trying to monitor the T-cell al-
loimmune response have been done in kidney trans-
plant patients. Among the most robust functional as-
says measuring T-cell alloreactivity, the IFN-F en-
zyme-linked immunosorbent spot (Elispot) assay has 
been shown in multiple reports to be capable of accu-
rately assess the frequency of alloreactive circulating 
memory/effector T-cells with donor-antigen or panel 
reactivity, both before and after transplantation, dis-
criminating patients with increased risk for TCMR 
and worse graft function evolution, even in absence of 
humoral allosensitization. Furthermore, our prelimi-
nary data of a very recent PoC-trial showed that ran-
domization of kidney transplant patients within the 
first two days post-transplantation by applying the 
IFN-gamma Elispot may allow safe personalization of 
the immunosuppression by using an early CNI-free 
protocol in renal transplant recipients identified as 
low-responder[37].  
Therefore, pre-transplant assessment of anti-donor 
memory/effector T-cell alloresponse using the IFN-ga-
mma Elispot may help to accurately discriminate pa-
tients that may safely benefit from receiving low-dose 
immunosuppression based on induction therapy with 
basiliximab (anti-CD25 monoclonal antibody) and 
low-dose TAC monotherapy, from others that should 
stay on higher immunosuppression such as the current 
gold-standard regimen sustained on basiliximab in-
duction and TAC/MMF/steroid triple-drug mainten-
ance therapy. Thus the randomized phase II trial called 
“Cellimin” will test the hypothesis that using the 
IFN-F to assess donor-specific memory/effector T-cell 
alloreactivity, the biomarker-driven low-dose immu-
nosuppression will be non-inferior with respect to bi-
opsy-proven TCMR/ABMR rate and graft function at 
12 months post-transplantation, compared to patients 
receiving a standard-of-care immunosuppressive 
therapy (Figure 4). 
First kidney transplant recipients that provide con-
sent to participate in the study will be evaluated pe-
ri-operatively for their anti-donor T-cell alloresponse 
using the IFN-gamma Elispot. Patients with frequen-
cies of alloreactive T cells above the defined cut-off 
(high-responder) will receive stand-of-care immuno-
suppression; patients identified as low-responder (be-
low the defined cut-off) will be randomised 1:1 into 
two groups:  
(i) Standard of care: the patients will be treated by 
standard-of-care immunosuppressive regimen based 
on TAC (achieving 4–8 ng/ml trough levels), MMF (1 g 
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Figure 4. The Cellimin Trial Design. 
The multicenter, randomized Cellimin trial is designed to verify the usefulness of the IFN FNial for stratification of kidney transplant patients into 
high/low responder according to their frequency of donor-reactive memory/effector-T cells. Low responder patients defined to have <25 reactive 
spots/300,000 PBMC will be identified by perioperative Elispot and randomized 1:1 into two groups receiving either standard triple-drug regimen or 
minimized therapy (monotherapy) with the aim to demonstrate non-inferiority if minimization is guided by this biomarker. High-responder patients 
will get standard therapy as well. 
 
bid) and steroids (according to KDIGO guidelines). 
(ii) Biomarker based minimization strategy: the low 
responders will be treated following a “low” immu-
nosuppression regimen (based on TAC monotherapy 
to achieve 8–10 ng/ml trough levels during the first 4 
weeks after transplantation and 4–8 ng/ml thereafter, 
MMF (1 g bid) during the first 7 days post-transplant 
and stopped thereafter) and steroids (tapering until 
discontinuation on month 2 post-transplant) 
All patients will receive 2 doses of Basiliximab 
(day 0 and day 4 after transplantation). In addition to 
the decision-making Elispot, several other biomarkers 
will be analysed during follow-up in order to see 
whether low/high-responder stratification can be fur-
ther improved and to understand better the mechan-
isms behind and stability of low/high response.  
To get the approval for all European clinical centres 
involved in the BIO-DrIM study by the regulatory 
authorities of the respective countries, we applied for 
the very recently implemented Voluntary Harmoniza-
tion Process (VHP) for multicentre trials in Europe. 
The European-wide multicenter study, Cellimin, got 
the VHP approval for our knowledge as the first In-
vestigator-Initiated Multicenter Trial (IIT). The trial 
was initiated very recently. 
Remini — a multicenter open-label single-arm Si-
mon’s two-stage phase II clinical trial aiming to pro-
vide evidence for efficacy and safety of the novel in-
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duction combinatory regimen with rATG and inflix-
imab to reach earl minimisation of immunosuppres-
sion after renal allotransplantation and a go/no go 
rule for further clinical development (From a bio-
marker with negative predictive value to a new target) 
The data from several groups, including those from 
members of the BIO-DrIM consortium, demonstrated 
an association between high frequencies of do-
nor-reactive memory/effector T cells as sign of T-cell 
sensitization already before transplantation and the 
incidence of acute rejections and poor 1-year graft 
function[11,12,17]. Recent data in an experimental rat 
kidney transplant model revealed that induced T-cell 
sensitization by pre-transplant adoptive transfer of 
donor-reactive memory/effector T cells up to levels 
comparable to patients at high risk (high-responder) 
required high-dose CNI-based immunosuppression for 
preserving long-term graft function[36]. The biomarker 
studies suggest that selective targeting of activated 
donor-specific memory/effector T cells might be a 
new strategy to switch high- into low-responders 
(from a biomarker to a target) — but how might this 
be feasible? 
Acute rejection rate in low-risk kidney transplant 
patients treated with quadruple immunosuppression 
based on basiliximab induction, tacrolimus, myco-
phenolate mofetil and steroids in Symphony or 
OSAKA trials doesn´t exceed 20%. Long term im-
munosuppression, however, is not only costly, but 
leads also to many undesirable side-effects. Minimiza-
tion of immunosuppression as early as possible and 
further reduction of acute rejection incidence is a goal 
of transplant research. Rabbit antithymocyte globulin 
(rATG, Thymoglobulin) is a polyclonal antibody ap-
proved for prevention of acute rejection in kidney 
transplantation. rATG has been shown to be effective 
tool to decrease T (and B) cell populations for several 
months and thus allowing safe reduction/minimization 
of other immunosuppressive drugs. Reducing clonal 
size of alloreactive T cells by rATG followed by 
low-dose IS revealed promising results but only in 
some patients. An alternative for reducing clonal size 
was the anti-CD52 monoclonal antibody, alemtuzu-
mab. Unfortunately, this antibody is not available 
longer for transplant patients as Sanofi after purchas-
ing Genzyme, took it from the market by business 
reasons.  
The disadvantage of this protocol is the alloanti-
gen-driven lymphopenia-induced proliferation of re-
maining donor-reactive memory/effector T cells es-
caping from deletion in high responder patients. Un-
selective depletion/targeting of almost all memo-
ry/effector T cells also attack protective memory 
against pathogens and increase the risk of infections. 
Therefore, increasing the pool of low-responders by 
specifically targeting donor-reactive effector/memory 
T cells would have a big advantage. In a pilot trial 
(Viklicky O et al., submitted[19]) we demonstrated that 
a novel induction protocol based on the combination 
of clonal size reduction (by low-dose alemtuzumab) 
and selective targeting of very recently (re)activated 
(allospecific) effector/memory T cells (expressing 
temporarily mTNF) as well as acute inflammation by 
the anti-TNF monoclonal antibody, infliximab, allows 
safe monotherapy (low-dose tacrolimus) as early as 
after day 3 post-transplantation in all kidney transplant 
patients, even in patients with high frequencies of do-
nor-specific IFN-gamma Elispot + cells before trans-
plantation. The 5-year data revealed excellent graft 
function and histology (almost no signs of chronic 
rejection). This data allows the formulation of the hy-
pothesis that after using the new induction protocol, 
the proportion of non-responders will increase and the 
incidence of acute rejection will remain low in tacro-
limus monotherapy treated patients. Besides clinical 
observations, several biomarker analysis using differ-
ent BIO-DrIM immune monitoring platforms are be-
ing planned to underline expected results, particularly 
the Elispot, molecular tolerance signature, and urinary 
IP-10 levels. 
Primary endpoint will be the evaluation of clinical 
response to the new protocol determined by the ab-
sence of the following outcomes up to 12 months 
post-transplantation: acute rejection, graft loss or poor 
graft function defined as eGFR<40 ml/min. Unfortu-
nately, the design of the study based on the promising 
pilot trial data had to be adapted to using rATG for 
initial reduction of clonal size as alemtuzumab is not 
available longer as suggested above.  This change 
might be associated with some risk to reproduce the 
promising data seen following alemtuzumab induction 
together with the anti-TNF approach. Therefore, the 
Remini trial is designed as Simon`s two-stage trial 
with interims analysis after 64 patients before enrol-
ling all 161 patients. 
Implementation of the Biomarker Test Analyses 
After selecting the biomarker portfolio for the clinical 
validation trials based on preliminary work and proof- 
of-concept trials, the consortium decided whether the 
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tests will be performed at a central core lab or under 
supervision of a core lab at the onsite labs. The com-
plexity of the method, the preanalytic prerequisites, 
and the time window in which the results have to be 
provided, determined this decision.  
Most critical was the standardization and imple-
mentation of the decision-making markers — the gene 
expression profile in liver biopsies and the IFN-ga-
mma Elispot in the peripheral blood in order to stratify 
the transplant patients according to their molecular 
tolerance signature into tolerant/non-tolerant liver tran-
splant recipients and their pre-transplant frequency of 
donor-reactive memory/effector T cells into low/high 
responder kidney transplant recipients, respectively.  
Molecular Tolerance Signature for Guiding 
Immunosuppression Withdrawal in Stable 
Long-term Liver Transplant Patients 
For the immunosuppression withdrawal study in sta-
ble long-term liver transplant patients the biomarker 
gene expression analyses by RT-PCR and microarray 
can be performed by a central core lab that process 
and analyse the samples collected from all clinical 
centres as the delivery of data within few weeks is 
sufficient to guide the recommendation of stepwise 
weaning until complete withdrawal. Although this str-
ategy reduces the challenges of interlab comparability, 
such as different equipment, procedures, technicians 
etc., extensive standardization, including preanalytics, 
intra-/inter-assay and inter-operator variability, had to 
be ensured. After ensuring these criteria, the clinical 
trial could be very recently started after we got the 
approval by the regulatory authorities few weeks ago. 
Identification of High/low Responder Renal 
Allograft Recipients by Quantifying the Pre- 
transplant Donor-specific Memory/effector 
T-cell Response 
In contrast, an onsite monitoring in each clinical cen-
tre is required for the perioperative stratification into 
high-responder/low-responder kidney transplant pa-
tients to identify the low-responder patients and to 
randomize the low-responder patients into the groups 
of standard or minimized immunosuppression, as the 
data has to be available within 48 hrs post-transplan-
tation. This required a dissemination of the test system 
(Elispot) to each clinical study centre lab and interlab 
comparisons to validate the robustness and correctness 
of the assay. In close collaboration between the core 
lab at Berlin, the study centre laboratories, and the 
provider of the Elispot system/test (GenID/AID), we 
were able to implement after 1.5 years intense work a 
well validated assay fulfilling the criteria required[38]. 
Most importantly, interlab comparisons confirmed 
correct categorization of almost all patients into 
high/low-responder according to the predefined cut- 
off of IFN FNdefined T-effector/memory cells/300,000 
PBMC (Figure 5). 
 
 
 
Figure 5. The interlab methodical validation of the IFN FNthodic assay. 
Extensive work was performed to standardize the decision-making Elispot. After implementation and training, several interlab comparisons were 
performed. The data shown here, exemplary demonstrate the correct categorization of all patients by two centers (Barcelona and Berlin) into 
high/low-responder groups. In the double-blinded interlab comparison, nine samples were categorized by both centers into low responder (non-primed) 
patients, two of them even near the cut-off level of 25 spots. The remaining nine patients were categorized as high-responders (memory) by both 
centers with levels between 50 and 400 spots. The data showed very high correlation between the two centers (R>0.8; p<0.01). Moreover, the varia-
tion (cv) was low in intralab and interlab comparison.     
The right panel shows exemplary the images for one low responder and one high-responder patient in triplets. 
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As the precision of the test is a key factor for the 
successful outcome of the clinical trial, the interlab 
comparison will be repeated every year. 
Exploratory Biomarker Studies 
In addition to the two decision-making tests described 
above, the consortium will analyse several parameters 
either in central core laboratories or in on-site labora-
tories in order to explore the values of further bio-
markers for stratification, safety, monitoring of thera-
py response etc. The collaboration with partners from 
the diagnostic industry will further improve the quali-
ty of the test performance, particularly for multi-par-
ameter flow cytometry and quantification of urinary 
IP-10 levels. Recently, we established in collaboration 
with industry several 10-color flow cytometry panels 
for quantifying different immune cell subsets in whole 
blood[20]. These panels were improved further for the 
BIO-DrIM studies and adapted to the recent Duraclo-
neTM technology allowing long-lasting storage and 
easy-to-handle procedure, and delivers even lower 
variability (Streitz et al., in preparation[20]). 
One additional goal is the identification of a mole-
cular tolerance signature in long-term stable kidney 
transplant patients in order to allow safe minimization 
of immunosuppression in operational tolerant patients, 
like in liver transplant patients. In several independent 
studies, a particular B-cell signature was most promi-
nently and robustly associated with stable drug-free 
kidney transplant recipients[5–10]. However, it is not 
clear whether this signature seen in stable drug-free 
patients weaned-off immunosuppression because of 
non-compliance or medical indication (mostly lym-
phoma), can be also seen in operationally tolerant pa-
tients who are still on immunosuppression. In contrast 
to liver, operational tolerance is a rather rare event 
after kidney transplantation and targeted weaning is 
ethically difficult because of the lower regenerative 
potency of renal allografts following undesired rejec-
tion. Therefore, another BIO-DrIM study of WP1 fo-
cuses on the evaluation of this signature in many 
long-term renal allograft recipients kept on different 
immunosuppressive schemes to get a better impres-
sion on the incidence of this signature and the impact 
of distinct drugs. Moreover, in a small multicentre 
study based in France, carefully selected long-term 
stable kidney transplant patients will be step-by-step 
weaned-off immunosuppression under intense clinical 
control and biomarker monitoring. Both trials are 
on-going.  
Discussion 
The aim of the consortium is to develop biomark-
er-driven immunosuppression for SOT patients in or-
der to change the presently used one-size-fits all 
strategy to a more personalized approach. Based on 
extensive preliminary work of both academic and in-
dustry partners of the consortium, ready-to-go bio-
marker tests using different technology platforms were 
selected and clinical studies were designed for their 
validation. Two BIO-DrIM studies will validate for 
the first time decision-making parameters for patient 
stratification in randomized multicentre studies. 
The following major challenges had to be faced 
during the start-up phase: 
(i) Implementation of a functional biomarker (IFN- 
gamma Elispot) at different study sites at the high 
performance quality that it is required for a deci-
sion-making parameter, 
(ii) Underestimation of the personal and financial 
resources needed for the preparation and performance 
of such complex multicentre IITs. The new VHP tool 
has significant advances but is also very challenging 
for an academic consortium consisting of several legal 
entities because of the short time lines for responses to 
comments predefined by the regulatory authorities,  
(iii) Limited interest by the majority of big pharma 
to implement biomarker-driven personalized therapies 
after marketing approval of a specific drug for the 
whole patient population; and unexpected changes in 
the marketing strategy of big pharma with major im-
pact on our consortium structure, the study design, 
and study population (need or re-designing Cellimin 
and Remini trials because of strategy changes by big 
pharma) 
(iv) Different reimbursement systems within Eu-
rope challenge the health-economic analyses. 
Nevertheless, the consortium made significant 
progress since its formation about two years ago. All 
but studies are carried out and results can be expected 
soon. It could be a big step forward on the way to 
personalized immunosuppression after SOT in order 
to improve the cost/benefit and side effect/efficacy 
ratio.  
Conclusion 
The implementation of biomarker-driven immuno-
suppression is challenging and requires a multicentre 
academic/industry partnership. The BIO-DrIM con-
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sortium might be a road model for such an approach. 
It includes joint activities for the development, valida-
tion, implementation, and analysis of biomarkers; the 
design, getting of approval, and performance of clini-
cal studies, accompanied by health-economic analyses 
(see accompanying paper). To implement the bio-
markers into daily routine, next steps after successful 
clinical trials have to be the registration as IVD by 
FDA and EMA. The regulatory rules are still quite 
different between Europe and US. Scientific advice 
meetings with both agencies in 2016 will help to de-
fine the next steps on the road more in detail.     
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